Eprosartan


Concise Prescribing Info
Indications/Uses
HTN.
Dosage/Direction for Use
Adult : PO Initial: 600 mg once daily. Maintenance: 400-800 mg/day in 1 or 2 divided doses.
Dosage Details
Oral
Hypertension
Adult: Initially, 600 mg once daily, adjusted according to response. Maintenance: 400-800 mg/day in 1 or 2 divided doses.
Elderly: No dosage adjustment needed.
Renal Impairment
Moderate to severe (CrCl <60 mL/min): Max: 600 mg/day.
Hepatic Impairment
No dosage adjustment needed.
Administration
May be taken with or without food.
Contraindications
Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Pregnancy.
Special Precautions
Patients w/ CHF, volume depletion, unstented unilateral or bilateral renal artery stenosis, significant aortic or mitral stenosis. Hepatic and renal impairment. Lactation.
Adverse Reactions
Fatigue, depression, hypertriglyceridaemia, abdominal pain, nausea, diarrhoea, vomiting, UTI, upper resp tract infection, rhinitis, pharyngitis, cough, viral infection, injury, dizziness, headache, arthralgia, back pain, rash, pruritus.
MonitoringParameters
Monitor BP, electrolytes, serum creatinine, BUN, K levels.
Overdosage
Symptom: Hypotension. Management: Symptomatic and supportive treatment.
Drug Interactions
May increase serum lithium levels and toxicity. Additive hyperkalaemic effect when used w/ K-sparing diuretics, K supplements or K-containing salt substitutes. NSAIDs may attenuate antihypertensive effect and result in deterioration of renal function including possible acute renal failure.
Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Action
Description: Eprosartan blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to AT1 receptor in many tissues (e.g. vascular smooth muscle, adrenal gland).
Onset: Approx 1-2 hr.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Absolute bioavailability: Approx 13%. Time to peak plasma concentration: Approx 1-2 hr (fasted state).
Distribution: Plasma protein binding: Approx 98%.
Metabolism: Minimally hepatic.
Excretion: Via bile and urine (approx 7% as unchanged drug, approx 2% as acyl glucuronide). Terminal elimination half-life: Approx 5-9 hr.
Storage
Store between 20-25°C.
Disclaimer: This information is independently developed by MIMS based on Eprosartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in